Day One Biopharmaceuticals develops targeted therapies for genetically defined cancers. Its lead product candidate, DAY101, is an oral brain-penetrant inhibitor in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor. Founded in 2018, Day One Biopharmaceuticals is headquartered in South San Francisco.